title: Clinical messages from the Treatment for Adolescents With Depression Study (TADS).
abstract: OBJECTIVE
  The purpose of this report was to summarize the key clinical messages from the Treatment for Adolescents with Depression Study (TADS).
  
  
  METHODS
  TADS is a National Institute of Mental Health (NIMH)-funded randomized controlled trial designed to evaluate the relative effectiveness of fluoxetine, cognitive-behavioral therapy (CBT), and the combination of fluoxetine plus CBT across acute treatment, maintenance treatment, and naturalistic follow-up periods among adolescents with major depressive disorder.
  
  
  RESULTS
  Findings revealed that 6 to 9 months of combined fluoxetine plus CBT should be the modal treatment from a public health perspective as well as to maximize benefits and minimize harms for individual patients.
  
  
  CONCLUSIONS
  The combination of fluoxetine and CBT appears to be superior to both CBT monotherapy and fluoxetine monotherapy as a treatment for moderate to severe major depressive disorder in adolescents.
authors.affiliation: Division of Neurosciences Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA. john.march@duke.edu
authors.forename: John S
authors.initials: JS
authors.lastname: March
authors.forename: Benedetto
authors.initials: B
authors.lastname: Vitiello
mesh_terms: D000293:Adolescent; D000294:Adolescent Behavior / Q000187:drug effects / Q000523:psychology; D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000523:psychology / Q000628:therapy; D004311:Double-Blind Method; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use*; D040261:Harm Reduction; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D010919:Placebos; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000706:statistics & numerical data*; D012107:Research Design; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D013405:Suicide / Q000523:psychology; D016896:Treatment Outcome; D006113:United Kingdom; D000092864:Suicide Prevention
chemical_list: D005473:Fluoxetine; D010919:Placebos; D017367:Selective Serotonin Reuptake Inhibitors